Operational Highlights
- Recorded highest ever revenue and PAT in Q3 FY2022.
- Total revenues increased by 18% and 44% on Q-o-Q and Y-o-Y basis respectively to ₹178.2 Cr in Q3FY22.
- EBITDA stood at ₹76.1 Cr with EBITDA margins at 42.7%.
- In 9MFY22, Domestic region contributed 26% followed by 40% from China, 14% from Europe, 13% from the USA and 6% RoW (74% of revenues from export).
- Gross margins reduced to 64.5% in Q3FY22 from 75.7% in Q3FY21.
- The incremental prices were marginally passed on and as the contracted ended in December, new contracts are on revised prices and will be reflected from next quarter.
- Acquired new clients sep-oct period.
- DCC plant was underutilised to 30-35% , rest of the products stood at 65-70% utilisation.
- ₹100Cr annual revenue from new products is anticipated at optimum utilisation.
- Addition of capacity and increasing customers wallet share will drive the future growth.
- Older products have better margins compared to new launches.
Performance chemicals
- 65% of revenues were contributed from performance chemicals.
- Increased realisations across all products.
- Strong volume offtake for BHA during Q3 FY22 compared to Q3 FY21.
Pharma chemicals
- 20% revenue contribution from pharma chemicals.
- Increased volume offtake across products.
- Improved realisations for DCC during Q3 FY22.
FMCG
- 15% revenue contribution from FMCG related chemicals.
- Increased volume offtake and improved realisations for all key products in Q3 FY22 compared to Q3 FY21.
New products
- PBQ and TBHQ are new products to be launched this quarter
- PBQ is an import substitute and most of the sales are focused in domestic region
- Only a few companies of which 2 from China are manufacturers for PBQ. The prices range from 20$ to 30$.
- PBQ is tricky product as it is oxidation reaction and any changes in colour will result in rejection by clients.
- TBHQ is more of export oriented product and used as stabiliser in edible oils.
- BHA and Ascorbyl palmitate goes hand in hand with TBHQ.
- TBHQ is more of catalytic reaction process.
- Hydroquinone will be the raw material used to make new products and will be procured from domestic markets.
- The company does not have plans on backward integration for the product until necessary.
Capex
-
- Two new plants commissioned in unit 3 for the new products(PBQ and TBHQ).
- FY22 capex spend stood at ₹150 Cr.
- Addition of capacities of MEHQ and Guaiacol by 20-30% in mid of march.